Aehr Test Systems Seeks Shareholder Approval for 2.8M New Equity Shares

Ticker: AEHR · Form: DEF 14A · Filed: Sep 10, 2025 · CIK: 1040470

Aehr Test Systems DEF 14A Filing Summary
FieldDetail
CompanyAehr Test Systems (AEHR)
Form TypeDEF 14A
Filed DateSep 10, 2025
Risk Levelmedium
Pages16
Reading Time19 min
Key Dollar Amounts$400 million
Sentimentmixed

Sentiment: mixed

Topics: Equity Incentive Plan, Shareholder Meeting, Executive Compensation, Stock Purchase Plan, Corporate Governance, Dilution Risk, Semiconductor Industry

Related Tickers: AEHR

TL;DR

**AEHR is asking shareholders to greenlight a massive 9.3% equity dilution, signaling a potential talent grab but watch out for your share value.**

AI Summary

AEHR TEST SYSTEMS (AEHR) is holding its Annual Meeting of Shareholders on October 20, 2025, to address several key proposals. Shareholders will vote on the election of six directors, including Rhea J. Posedel and Gayn Erickson. A significant proposal involves amending the 2023 Equity Incentive Plan to increase shares reserved for issuance by an additional 2,500,000 shares of common stock. Furthermore, the company seeks approval to amend its 2006 Employee Stock Purchase Plan, increasing reserved shares by an additional 300,000 shares of common stock. Shareholders will also ratify BPM LLP as the independent auditor for the fiscal year ending May 29, 2026, and cast advisory votes on executive compensation and the frequency of future compensation votes. As of the August 28, 2025 record date, there were 29,968,988 shares of common stock outstanding and entitled to vote.

Why It Matters

This DEF 14A filing is crucial for investors as it outlines significant dilution potential and compensation strategy. The proposed increase of 2,500,000 shares for the 2023 Equity Incentive Plan and 300,000 shares for the 2006 Employee Stock Purchase Plan could dilute existing shareholder value by approximately 9.3% based on 29,968,988 shares outstanding. This move aims to attract and retain talent in a competitive semiconductor test equipment market, directly impacting AEHR's ability to innovate and grow against rivals. Employees stand to benefit from enhanced equity incentives, while customers could see improved product development if these plans foster innovation. The advisory votes on executive compensation also signal the company's commitment to governance, influencing investor confidence.

Risk Assessment

Risk Level: medium — The primary risk stems from the proposed increase of 2,500,000 shares for the 2023 Equity Incentive Plan and 300,000 shares for the 2006 Employee Stock Purchase Plan. With 29,968,988 shares outstanding as of August 28, 2025, this represents a potential dilution of approximately 9.3% for existing shareholders, which could negatively impact earnings per share and stock price.

Analyst Insight

Investors should carefully evaluate the potential dilution from the proposed equity plan amendments against the benefits of employee retention and motivation. Consider voting against Proposals 2 and 3 if you believe the dilution is excessive or if the company's growth prospects don't justify such an increase in share-based compensation.

Financial Highlights

debt To Equity
0.0
revenue
$130.7M
operating Margin
17.0%
total Assets
$209.5M
total Debt
$0.0M
net Income
$15.3M
eps
$0.51
gross Margin
50.0%
cash Position
$105.1M
revenue Growth
+26.0%

Key Numbers

  • 2,500,000 — Additional shares for 2023 Equity Incentive Plan (Proposed increase in shares reserved for issuance)
  • 300,000 — Additional shares for 2006 Employee Stock Purchase Plan (Proposed increase in shares reserved for issuance)
  • 29,968,988 — Shares of common stock outstanding (As of Record Date August 28, 2025, entitled to vote)
  • October 20, 2025 — Annual Meeting Date (Date of the 2025 Annual Meeting of Shareholders)
  • August 28, 2025 — Record Date (Shareholders of record entitled to vote)
  • 9.3% — Potential Dilution (Combined increase of 2,800,000 shares relative to 29,968,988 outstanding shares)

Key Players & Entities

  • AEHR TEST SYSTEMS (company) — Registrant
  • Gayn Erickson (person) — President and Chief Executive Officer, Nominee for Director
  • Rhea J. Posedel (person) — Nominee for Director
  • Fariba Danesh (person) — Nominee for Director
  • Laura Oliphant (person) — Nominee for Director
  • Geoffrey G. Scott (person) — Nominee for Director
  • Howard T. Slayen (person) — Nominee for Director
  • BPM LLP (company) — Independent registered public accounting firm
  • Chris P. Siu (person) — Executive Vice President of Finance and Chief Financial Officer
  • SEC (regulator) — Securities and Exchange Commission

FAQ

What are the key proposals for AEHR Test Systems' 2025 Annual Meeting?

AEHR Test Systems' 2025 Annual Meeting includes proposals to elect six directors, approve an amendment to the 2023 Equity Incentive Plan for an additional 2,500,000 shares, approve an amendment to the 2006 Employee Stock Purchase Plan for an additional 300,000 shares, ratify BPM LLP as auditor, and hold advisory votes on executive compensation and its frequency.

How many additional shares is AEHR Test Systems proposing to issue under its equity plans?

AEHR Test Systems is proposing to increase the shares reserved for issuance by an additional 2,500,000 shares under the 2023 Equity Incentive Plan and an additional 300,000 shares under the 2006 Employee Stock Purchase Plan, totaling 2,800,000 new shares.

Who are the nominees for the Board of Directors at AEHR Test Systems?

The six nominees for the Board of Directors at AEHR Test Systems are Rhea J. Posedel, Gayn Erickson, Fariba Danesh, Laura Oliphant, Geoffrey G. Scott, and Howard T. Slayen.

What is the record date for voting at AEHR Test Systems' Annual Meeting?

The record date for determining shareholders entitled to vote at AEHR Test Systems' Annual Meeting is the close of business on August 28, 2025.

What is the potential dilution impact of the proposed equity plan amendments for AEHR Test Systems?

The proposed increase of 2,800,000 shares across two equity plans, compared to 29,968,988 shares outstanding as of August 28, 2025, represents a potential dilution of approximately 9.3% for existing AEHR Test Systems shareholders.

Is the vote on executive compensation binding for AEHR Test Systems?

No, the vote on the compensation of AEHR Test Systems' named executive officers is advisory (non-binding). The Board and Compensation Committee will consider the outcome but are not legally bound by it.

Where will AEHR Test Systems' Annual Meeting be held?

The Annual Meeting for AEHR Test Systems will be held at the Company's corporate headquarters located at 400 Kato Terrace, Fremont, California 94539.

Who is the independent registered public accounting firm for AEHR Test Systems?

BPM LLP has been selected as AEHR Test Systems' independent registered public accounting firm for the fiscal year ending May 29, 2026, and shareholders will vote on its ratification.

How can AEHR Test Systems shareholders access proxy materials?

AEHR Test Systems shareholders can access proxy materials online at www.aehr.com under 'Investor Relations' and 'Annual Reports/Proxy Statements' or at www.investorvote.com/AEHR. They can also request paper or email copies by phone or email.

What is the deadline for shareholder proposals for AEHR Test Systems' 2026 Annual Meeting?

Shareholder proposals for inclusion in AEHR Test Systems' 2026 proxy materials must be received by May 14, 2026. Other shareholder proposals and director nominations must be received between May 23, 2026, and June 22, 2026.

Industry Context

AEHR TEST SYSTEMS operates in the semiconductor testing equipment market, a critical segment of the broader semiconductor industry. This industry is characterized by rapid technological advancements, cyclical demand tied to global electronics production, and significant capital investment requirements. Key trends include increasing complexity of chips, demand for higher performance and reliability, and the growth of emerging markets like AI and automotive electronics, all of which drive the need for advanced testing solutions.

Regulatory Implications

The proposed increase in authorized shares for equity and employee stock purchase plans could lead to increased shareholder scrutiny regarding potential dilution. Companies must comply with SEC regulations regarding proxy solicitations and disclosures. Ratification of the independent auditor ensures adherence to auditing standards and financial reporting integrity.

What Investors Should Do

  1. Review the proposed amendments to the 2023 Equity Incentive Plan and 2006 Employee Stock Purchase Plan.
  2. Evaluate the company's executive compensation practices.
  3. Consider the ratification of BPM LLP as the independent auditor.

Key Dates

  • 2025-10-20: Annual Meeting of Shareholders — Shareholders will vote on director elections, equity plan amendments, auditor ratification, and executive compensation.
  • 2025-08-28: Record Date — Establishes the shareholders eligible to vote at the Annual Meeting.
  • 2026-05-29: Fiscal Year End — The period for which BPM LLP is being ratified as the independent auditor.

Glossary

DEF 14A
A filing with the U.S. Securities and Exchange Commission (SEC) that provides detailed information about a company's annual meeting, including proposals to be voted on by shareholders. (This document outlines the key proposals and information relevant to AEHR TEST SYSTEMS's upcoming shareholder meeting.)
Equity Incentive Plan
A plan that allows a company to grant stock options, restricted stock, or other equity-based awards to employees and executives. (AEHR is seeking to increase the number of shares available under its 2023 Equity Incentive Plan, which could impact future dilution.)
Employee Stock Purchase Plan (ESPP)
A plan that allows employees to purchase company stock, often at a discount, through payroll deductions. (AEHR is seeking to increase the number of shares available under its 2006 ESPP, which could impact future dilution.)
Record Date
A specific date set by a company to determine which shareholders are eligible to receive notice of and vote at a shareholder meeting. (Determines who can vote on the proposals at AEHR's Annual Meeting.)
Proxy Statement
A document provided to shareholders before a shareholder meeting that contains information about the matters to be voted on and how to vote. (This is the document containing the information presented here, guiding shareholder decisions.)
Independent Registered Public Accounting Firm
An external audit firm hired by a company to examine its financial statements and provide an independent opinion on their fairness and accuracy. (Shareholders are asked to ratify the selection of BPM LLP for the upcoming fiscal year.)

Year-Over-Year Comparison

This filing indicates a significant increase in the number of shares reserved for equity and employee stock purchase plans, totaling 2,800,000 additional shares. This represents a potential dilution of approximately 9.3% relative to the 29,968,988 shares outstanding as of the record date. The filing also includes proposals for advisory votes on executive compensation and the frequency of such votes, which are standard components of annual proxy statements.

Filing Stats: 4,767 words · 19 min read · ~16 pages · Grade level 13.3 · Accepted 2025-09-10 16:01:33

Key Financial Figures

  • $400 million — technology company, where she oversaw a $400 million annual revenue photonics business with

Filing Documents

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 35 CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS 48

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 48 REPORT OF AUDIT COMMITTEE 50 COMPLIANCE WITH SECTION 16(a) OF THE SECURITIES EXCHANGE ACT OF 1934 51

FINANCIAL STATEMENTS

FINANCIAL STATEMENTS 51 OTHER MATTERS 51 Table of Contents AEHR TEST SYSTEMS 400 Kato Terrace Fremont, California 94539 ______________________ PROXY STATEMENT ______________________ 2025 ANNUAL MEETING OF SHAREHOLDERS This Proxy Statement is being furnished to the shareholders of Aehr Test Systems, a California corporation ("Aehr" or the "Company"), in connection with the solicitation of proxies by the Board of Directors (the "Board"), for use at the 2025 Annual Meeting of Shareholders of the Company (the "Annual Meeting"), to be held on Monday, October 20, 2025 at 4:00 p.m. local time, and at any postponements, adjournments or other delays thereof. We refer to this annual meeting, as it may be postponed, adjourned or delayed, as the Annual Meeting. At the Annual Meeting, the shareholders will be asked: 1. To elect six directors of the Company to hold office until the next annual meeting or the election of their successors. 2. To approve an amendment to the Company's 2023 Equity Incentive Plan to increase the number of shares of common stock reserved for issuance thereunder by an additional 2,500,000 shares of common stock. 3. To approve an amendment to the Company's Amended and Restated 2006 Employee Stock Purchase Plan to increase the number of shares reserved for issuance thereunder by an additional 300,000 shares of common stock. 4. To ratify the selection of BPM LLP as the Company's independent registered public accounting firm for the fiscal year ending May 29, 2026. 5. To approve, on an advisory (non-binding) basis, the compensation of the Company's named executive officers. 6. To hold an advisory (non-binding) vote on the frequency of future advisory (non-binding) votes on the compensation of the Company's named executive officers. 7. To transact such other business as may properly come before the Annual Meeting or any postponements or adjournments thereof. The Board has fixed the close of business on August 28, 2025 as

View Full Filing

View this DEF 14A filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.